Business
Neurocrine Biosciences Presents Data on Improvements Over Time with Long-Term Use of INGREZZA® (valbenazine) Capsules in Older and Elderly Patients at the American Association for Geriatric Psychiatry 2023 Annual Meeting
SAN DIEGO, March 3, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it will present data analyzing the long-term outcomes of
About this update from Neurocrine Biosciences, Inc.
[{"type":"text","content":"SAN DIEGO, March 3, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it will present data analyzing the long-term outcomes of treating tardive dyskinesia (TD) with INGREZZA® (valbenazine) capsules in older (≥55 years) and elderly (≥65 years) patients from two studies (KINECT™ 3-extension and KINECT™ 4). These data (Poster #NR-36, Improvements Over Time with Long-Term Valbenazine in Older and Elderly Patients with Tardive Dyskinesia) are being presented at the American Association for Geriatric Psychiatry (AAGP) 2023 Annual Meeting from March 3–6 in New Orleans.\n\n \n \n \n \n \n \n\n \nThe data demonstrated that long-term treatment with once-daily INGREZZA led to clinically meaningful reductions of TD symptoms in both older patients with TD and elderly patients. At 48 weeks of INGREZZA treatment, >80 percent of participants in the ≥65 years age group met the >50 percent improvement in the Abnormal Involuntary Movement Scale (AIMS) response threshold. Analyses included the following: \nMean change from baseline in AIMS total scorePercentage of patients meeting AIMS response thresholds, including ≥50 percent improvement from baseline (protocol-defined response) and ≥70 percent improvement from baseline (stringent response)Global response thresholds, including Clinical Global Impression of Change-Tardive Dyskinesia (CGI-TD) and Patient Global Impression of Change (PGIC) defined as \"much improved\" or \"very much improved\" (score ≤2)Similar results were found in the ≥55 years age group. Mean changes from baseline to week 48 in psychiatric symptom scale scores were minimal, indicating maintenance of psychiatric stability in both age groups.\n\"Older and elderly adults treated with dopamine receptor blocking agents, including antipsychotics, have an increased risk for developing TD,\" said Eiry W. Roberts, MD, Chief Medical Officer at Neurocrine Biosciences. \"The results of this post-hoc analysis regarding long-term use of INGREZZA in this vulnerable patient population can be used to better inform treatment decisions for those experiencing TD.\"\nThe Diagnostic Statistical Manual of Mental Disorders (DSM-5-TR) notes that middle-aged and elderly individuals have an increased risk for TD.\nKey findings from the data analyses include:\nIn both age groups, mean improvements in AIMS total score increa...